About the Journal
Drug Discovery and Development is an international journal that covers the interdisciplinary issues related to drug discovery, its design and development in to suitable dosage forms or delivery systems. The scope of the journal encompasses research papers, reviews, short communications and letters to editor with novel findings capable of contributing to the state of knowledge in the following relevant areas:
- Rational and structure-based drug design
- Novel drug delivery
- Targeted and controlled drug delivery against various diseases
- Recent trends in QSAR
- Natural products and their development as effective dosage forms/delivery systems/drug products
- Modulation of biopharmaceutical properties of drug
- Use of novel technique/tool for activity study or evaluation of drug/dosage forms/delivery systems
- Improving bioavailability of drugs
- Herbal drug delivery systems (for cancer, diabetes etc.)
- Formulation development
- Isolation of active compounds and activity analysis from herbs/medicinal plants
- Modification in the existing drugs and plant-derived active constituents.
The journal is indexed in Google Scholar, Citationbase, PhcogBase, Index Pharmacus, SCIENBASE, Sci-Lit and Dimensions.
Current Issue
Vol. 2 No. 2 (2026): Drug Discovery and Development
This issue of Drug Discovery and Development highlights critical advances across drug design, targeted delivery, and pharmaceutical ecotoxicology. In molecular chemistry, research showcases the design, synthesis, and biological evaluation of pyrazole and imidazole derivatives as promising core scaffolds for novel drug discovery. In advanced therapeutics, featured studies explore glycerosomes as sophisticated vesicular delivery systems, detailing a novel griseofulvin-loaded glycerosomal nanogel for targeted topical management of onychomycosis, as well as the in vivo antifungal evaluation of Parmelia perlata extracts. Complementing these therapeutic innovations, the issue addresses environmental safety by examining the ecotoxicological risks of clinical SSRIs (specifically sertraline and fluoxetine) on freshwater fish species. Together, these contributions bridge molecular design, delivery engineering, and environmental impact assessment.
Published:
2026-07-24
